Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 4/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2656868 | 0.95 | ADORA2A (0.66) | ADORA2ACYP2C9LMNAL3MBTL1ALDH1A1 | |
| SCHEMBL17817590 | 0.94 | ADORA2A (0.64) | ADORA2ACYP2C9LMNAL3MBTL1ALDH1A1 | |
| SCHEMBL7142997 | 0.94 | ADORA2A (0.64) | ADORA2ACYP2C9LMNAL3MBTL1ALDH1A1 | |
| SCHEMBL4112093 | 0.90 | ADORA2A (0.70) | ADORA2ACYP2C9LMNAL3MBTL1ALDH1A1 | |
| SCHEMBL15480444 | 0.90 | ALDH1A1 (0.68) | LMNAALDH1A1USP2MAPK1NPC1 | |
| SCHEMBL15480445 | 0.88 | ALDH1A1 (0.67) | LMNAALDH1A1USP2MAPK1NPC1 | |
| SCHEMBL15480447 | 0.88 | ALDH1A1 (0.67) | LMNAALDH1A1USP2MAPK1NPC1 | |
| SCHEMBL15480448 | 0.88 | ALDH1A1 (0.67) | LMNAALDH1A1USP2MAPK1NPC1 | |
| SCHEMBL15480450 | 0.88 | ALDH1A1 (0.67) | LMNAALDH1A1USP2MAPK1NPC1 | |
| SCHEMBL13681851 | 0.85 | CYP2C9 (0.56) | ADORA2ACYP2C9LMNAALDH1A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2091947-A2 | GLUCOKINASE ACTIVATORS | Takeda San Diego, Inc. (US) | 2009-08-26 | — | — | EP | claimed |
| EP-2001875-A2 | GLUCOKINASE ACTIVATORS | Takeda San Diego, Inc. (US) | 2008-12-17 | — | — | EP | claimed |
| WO-2008079787-A2 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2008-07-03 | — | — | WO | claimed |
| WO-2007104034-A2 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2007-09-13 | — | — | WO | claimed |
| US-RE49594-E1 | Apelin receptor (APJ) agonists and uses thereof | RESEARCH TRIANGLE INSTITUTE (US) | 2023-08-01 | — | — | US | disclosed |
| US-11535630-B2 | Apelin receptor (APJ) agonists and uses thereof | RESEARCH TRIANGLE INSTITUTE (US) | 2022-12-27 | — | — | US | disclosed |
| EP-2484342-A1 | Hair resiliency / body improver and hair cosmetic | Shiseido Company, Limited (JP) | 2012-08-08 | — | — | EP | disclosed |
| EP-2324028-A2 | THERAPEUTIC AGENTS 414 | AstraZeneca AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010015849-A2 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | WO | disclosed |
| US-20090233975-A1 | Hair resiliency/body improver and hair cosmetic | SHISEIDO COMPANY, LTD. (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-2091947-A2 | GLUCOKINASE ACTIVATORS | Takeda San Diego, Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| EP-2001875-A2 | GLUCOKINASE ACTIVATORS | Takeda San Diego, Inc. (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2008079787-A2 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| EP-1911750-A1 | AGENT FOR IMPROVEMENT IN BOUNCE/BODY OF HAIR, AND HAIR COSMETIC | Shiseido Company, Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007104034-A2 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| EP-1590337-A1 | ACYLAMINOTHIAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME AS BETA-AMYLOID PEPTIDE PRODUCTION INHIBITORS | Sanofi-Aventis (FR) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004067520-A1 | ACYLAMINOTHIAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME AS BETA-AMYLOID PEPTIDE PRODUCTION INHIBITORS | SANOFI-AVENTIS (FR) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233975-A1 | Hair resiliency/body improver and hair cosmetic | MC1R, PNISR, HCRTR1 | ADORA2A 644/4885CYP2C9 837/4885LMNA 1747/4885 |
| US-11535630-B2 | Apelin receptor (APJ) agonists and uses thereof | APLNR, AP1G1, APMAP | ADORA2A 201/4885CYP2C9 4709/4885LMNA 2587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.